In the last trading session, 1.37 million Celldex Therapeutics Inc. (NASDAQ:CLDX) shares changed hands as the company’s beta touched 1.55. With the company’s per share price at $33.20 changed hands at $0.34 or 1.03% during last session, the market valuation stood at $2.20B. CLDX’s last price was a discount, traded about -60.18% off its 52-week high of $53.18. The share price had its 52-week low at $22.11, which suggests the last value was 33.4% up since then. When we look at Celldex Therapeutics Inc.’s average trading volume, we note the 10-day average is 2.4 million shares, with the 3-month average coming to 955.67K.
Analysts gave the Celldex Therapeutics Inc. (CLDX) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.20. If we narrow down to specifics, the data shows that 0 out of 4 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 1 recommended CLDX as a Hold, 3 felt it is a Buy and 0 rated the stock as Underweight. Celldex Therapeutics Inc.’s EPS for the current quarter is expected to be -0.68.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Celldex Therapeutics Inc. (NASDAQ:CLDX) trade information
Instantly CLDX was in green as seen at the end of in last trading. With action -19.50%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -16.29%, with the 5-day performance at -19.50% in the red. However, in the 30-day time frame, Celldex Therapeutics Inc. (NASDAQ:CLDX) is -13.70% down. Looking at the short shares, we see there were 8.41 million shares sold at short interest cover period of 12.96 days.
The consensus price target for the stock as assigned by Wall Street analysts is 58, meaning bulls need an upside of 42.76% from its current market value. According to analyst projections, CLDX’s forecast low is 44 with 63 as the target high. To hit the forecast high, the stock’s price needs a -89.76% plunge from its current level, while the stock would need to soar -32.53% for it to hit the projected low.
Celldex Therapeutics Inc. (CLDX) estimates and forecasts
Data shows that the Celldex Therapeutics Inc. share is performing relatively much not better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -20.90% over the past 6 months, a 6.02% in annual growth rate that is considerably lower than the industry average of 17.70%. Year-over-year growth is forecast to reach -40.70% down from the last financial year.
Consensus estimates given by 9 financial analysts project the company’s revenue in the current quarter to hit an average of 920k. 9 analysts are of the opinion that Celldex Therapeutics Inc.’s revenue for the current quarter will be 910k. The company’s revenue for the corresponding quarters a year ago was 1.52M and 4.13M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -39.40%. The estimates for the next quarter sales put growth at -78.00%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 27.41%. The 2024 estimates are for Celldex Therapeutics Inc. earnings to increase by 15.41%.
CLDX Dividends
Celldex Therapeutics Inc. is expected to release its next quarterly earnings report in October.
Celldex Therapeutics Inc. (NASDAQ:CLDX)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 0.30% of Celldex Therapeutics Inc. shares while 107.31% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 107.63%. There are 107.31% institutions holding the Celldex Therapeutics Inc. stock share, with WELLINGTON MANAGEMENT GROUP LLP the top institutional holder. As of 2024-06-30, the company held 13.718% of the shares, roughly 8.08 million CLDX shares worth $298.89 million.
FMR LLC holds the second largest percentage of outstanding shares, with 13.2988% or 7.83 million shares worth $289.76 million as of 2024-06-30.
